Mona Al Mukaddam, M.D., M.S.
Associate Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)
Department: Medicine
Contact information
3rd floor Penn Medicine University City
3737 Market Street
Philadelphia, PA 19104
3737 Market Street
Philadelphia, PA 19104
Office: 215-662-9905
Links
Report on a patient with a rare bone disease correctly diagnosed at the Penn Bone Center
International Fibrodysplasia Ossificans Progressiva Association
Penn Primary Care Podcast discussing osteoporosis Hosted by Drs Amber Bird, Deepa Rani Nandiwada and Mona Al Mukaddam
Global CME on treatment considerations in Fibrodysplasia Ossificans Progressiva (FOP)
Commentary regarding type 1 diabetes and bone in medpage today
Webinar on COVID-19 vaccinations in FOP patients
Remembering Carol Orzel, FOP patient, who donated her skeleton to the the mutter museum.
Webinar for BMT organization on "Bone Health after Transplant"
Penn bone Center featured in Penn Medicine Women's health newsletter
CDC sponsored virtual grand round on evaluation and management of bone health in patients with Thalassemia https://www.cdc.gov/ncbddd/thalassemia/webinar-archives.html
CME titled "First Do No Harm: Realizing Timely Diagnosis and Treatment for Patients with Fibrodysplasia Ossificans Progressiva"
Endocrinology Spotlight Series: Management of Calcium and Metabolic Bone Disorders Expert Guidance for Challenging Cases
Podcast on Women's Health in FOP
Official website for International Clinical Council on Fibrodysplasia Ossificans Progressiva
Interviewed for a Penn primary care podcast to discuss osteoporosis
Penn Bone Center
Interviewed by checkrare after Palovarotene was approved by the FDA and the first and only treatment for FOP.
Report on a patient with a rare bone disease correctly diagnosed at the Penn Bone Center
International Fibrodysplasia Ossificans Progressiva Association
Penn Primary Care Podcast discussing osteoporosis Hosted by Drs Amber Bird, Deepa Rani Nandiwada and Mona Al Mukaddam
Global CME on treatment considerations in Fibrodysplasia Ossificans Progressiva (FOP)
Commentary regarding type 1 diabetes and bone in medpage today
Webinar on COVID-19 vaccinations in FOP patients
Remembering Carol Orzel, FOP patient, who donated her skeleton to the the mutter museum.
Webinar for BMT organization on "Bone Health after Transplant"
Penn bone Center featured in Penn Medicine Women's health newsletter
CDC sponsored virtual grand round on evaluation and management of bone health in patients with Thalassemia https://www.cdc.gov/ncbddd/thalassemia/webinar-archives.html
CME titled "First Do No Harm: Realizing Timely Diagnosis and Treatment for Patients with Fibrodysplasia Ossificans Progressiva"
Endocrinology Spotlight Series: Management of Calcium and Metabolic Bone Disorders Expert Guidance for Challenging Cases
Podcast on Women's Health in FOP
Official website for International Clinical Council on Fibrodysplasia Ossificans Progressiva
Interviewed for a Penn primary care podcast to discuss osteoporosis
Penn Bone Center
Interviewed by checkrare after Palovarotene was approved by the FDA and the first and only treatment for FOP.
Education:
BS
American University of Beirut, Lebanon, 2001.
MD
American University of Beirut, Lebanon, 2005.
MS
University of Pennsylvania, Institute of Translational Medicine and Therapeutics, 2013.
Permanent linkBS
American University of Beirut, Lebanon, 2001.
MD
American University of Beirut, Lebanon, 2005.
MS
University of Pennsylvania, Institute of Translational Medicine and Therapeutics, 2013.
Description of Clinical Expertise
Metabolic bone and calcium disorders including osteoporosis, Paget's disease, hypo- and hyper-parathyroidism as well as bone diseases related to transplant, medications (example aromatase inhibitors and glucocorticoids) and iron overload.Rare bone disease including Fibrodysplasia Ossificans Progressiva and hypophosphatasia.
Description of Research Expertise
Clinical research in Fibrodysplasia Ossificans Progressiva.Evaluation of osteoporosis and the effects of treatment/diseases on "bone quality" using high resolution imaging of bone (uMRI).
Selected Publications
Patricia Delai, Mona Al Mukaddam, Geneviève Baujat, Carmen De Cunto, Edward C. Hsiao, Richard Keen, Kim Croskery, Jean-Luc Delhay, Christelle Pommie, Robert J. Pignolo: Incidence and management of skin adverse events in patients receiving palovarotene for the treatment of fibrodysplasia ossificans progressiva. Poster Presentation at ICCBH Salzburg, Austria June 2024.Richard Keen, Robert J. Pignolo, Mona Al Mukaddam, Geneviève Baujat, Angela M. Cheung, Carmen De Cunto, Edward C. Hsiao, Jean-Luc Delhay, Fei Shih, Andrew Strahs, Frederick S. Kaplan: Assessments of bone mineralisation, strength and fracture of the lumbar spine in patients with fibrodysplasia ossificans progressiva treated with palovarotene: Data from the phase III MOVE trial and a phase II open-label extension Poster Presentation at ICCBH Salzburg, Austria June 2024.
Javier Ocampo Mascaro, Richie Tran, Staci Kallish, Jessica Berman, Mona Al Mukaddam: Clinical Features Of Adult Hypophosphatasia And Correlation Between Laboratory Findings And Patient’s Symptomatology: A Retrospective Review At The Penn Bone Center. Presidental Poster Session Endocrine Society Annual Meeting June 2024.
Javier Ocampo Mascaro, Pamela Wax, Mona Al Mukaddam: Adult-Onset Hypophosphatasia Presenting as Low Alkaline Phosphatase Level Following Denosumab Use for Osteoporosis. Presidental Poster Endocrine Society Annual Meeting June 2024.
Deborah Wenkert, Frederick S. Kaplan, Robert J. Pignolo, Edward C. Hsiao, Mona M Al Mukaddam, Eric Soliman, Victoria Smith, Pankaj Bhargava: ANDECAL, A Phase 2/3 study to determine the efficacy of the MMP9-inhibitor Andecaliximab to block new heterotopic ossification in FOP: Methodology for Part 1 of the Study Poster Presentation at ICCBH Salzburg, Austria June 2024.
Edna E. Mancilla, Geneviève Baujat, Mona Al Mukaddam, Javier Bachiller-Corral, Staffan K. Berglund, Carmen De Cunto, Patricia Delai, Richard Keen, Riccardo Papa, Robert J. Pignolo, Sally Lanar, Alexia Marrel, Alexander Artyomenko, Kim Croskery, Christelle Pommie, Edward C. Hsiao: The impact of palovarotene on patients with fibrodysplasia ossificans progressiva: Results from participant interviews in the phase III PIVOINE trial. Poster Presentation at ICCBH Salzburg, Austria June 2024.
Lounev V, Groppe JC, Brewer N, Wentworth KL, Smith V, Xu M, Schomburg L, Bhargava P, Al Mukaddam M, Hsiao EC, Shore EM, Pignolo RJ, Kaplan FS: Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice. J Bone Miner Res May 2024.
Bassam AlHamer, Ajit Singh, Carmen Patrascu, Mona Al Mukaddam: Tumor induced osteomalacia due to sarcomatoid non-small cell lung carcinoma confounded by drug-induced Fanconi syndrome JCEM Case Reports 2024.
Pignolo RJ, Al Mukaddam M, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, Le Quan Sang KH, Grogan DR, Marino R, Strahs AR, Kaplan FS.: Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. BMC Med Res Methodol Nov 2023.
Pignolo RJ, Al Mukaddam M, Baujat G, Brown MA, De Cunto C, Hsiao EC, Keen R, Le Quan Sang KH, Grogan DR, Marino R, Strahs AR, Kaplan FS.: Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva. BMC Med Res Methodol Nov 2023.